Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ADP + ATP
ATP + ADP
isotope exchange reaction (in presence of radiolabeled ADP and ATP but in absence of other reactants, meaning without NMN synthesis) requires high-energy phosphorylated NAMPT
-
-
r
ATP + H2O
ADP + phosphate
DELTAG° = -7.3, in presence of NAMPT slow steady-state reaction after initial burst, ATPase activity in absence of other substrates, but can be modulated by addition of single substrates and mixtures
-
-
?
ATP + NAMPT
ADP + phospho-NAMPT
autophosphorylation (DELTAG° = 1.9 kcal/mol, Keq = 0.047) is unfavourable and appears as initial burst of ADP generation
at 2.5 mM ATP and 46 microM NAMPT 77% of NAMPT is phosphorylated (proposed: His247 phospho-NAMPT), hydrolysis of phospho-NAMPT at 0.8/min, active phosphorylated NAMPT species neither isolated nor characterized yet
-
r
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
nicotinamide + 5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
nicotinamide + alpha-D-5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
nicotinamide + alpha-D-5-phosphoribosyl 1-diphosphate + ATP + H2O
nicotinamide mononucleotide + diphosphate + ADP + phosphate
DELTAG° = -1.0 kcal/mol, Keq = 5.0, reversion of the preestablished equilibrium in a non-ATP-coupled reaction, thermodynamic switch of the product-to-substrate ratio towards NMN production compared to the non-ATP-coupled reaction with an energy difference of -2.1 kcal/mol (meaning only 2.1 kcal/mol of 7.3 kcal/mol of the energy from ATP hydrolysis coupled to NMN formation), formation or hydrolysis of high-energy phosphorylated NAMPT may be rate limiting for overall ATP-coupled NMN synthesis
in presence of 2-2.5 mM ATP: 1 mol ADP per NMN formed (stoichiometric coupling ratio, R = 1), under optimal conditions (2 microM nicotinamide, 100 microM PRPP, 2.5 mM ATP, 5 mM Mg2+): R increases linearly with increasing diphosphate concentration
-
r
nicotinamide + alpha-D-5-phosphoribosyl-1-diphosphate
nicotinamide mononucleotide + diphosphate
nicotinamide D-ribonucleotide + diphosphate
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
phospho-NAMPT + H2O
NAMPT + phosphate
DELTAG° = -9.2 kcal/mol
-
-
?
additional information
?
-
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
specific for nicotinamide, no substrates: thymine, 5-bromouracil, nicotinic acid adenine dinucleotide
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
key enzyme in the regulation of NAD+ biosynthesis from the natural precursor nicotinamide
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
reaction is reversible as dictated by the equilibrium constant K, [NMN][PPi]/([NM][PRPP]) of 0.14, which agrees well with the ratio of second-order rate constants for forward and backward reactions, K of0.16
-
-
r
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
pre-B-cell colony enhancing factor
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
key enzyme in the regulation of NAD+ biosynthesis, regulates the silent regulator protein 2, i.e. Sir2, activity, the enzyme has a metabolic regulatory function by up- and downregulation of proteins, overview
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
beta-nicotinamide
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
first step in NAD synthesis from nicotinamide
-
?
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
nicotinamide D-ribonucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
-
-
-
?
nicotinamide + 5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
-
-
-
-
?
nicotinamide + 5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
-
-
-
-
?
nicotinamide + alpha-D-5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
-
-
-
r
nicotinamide + alpha-D-5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
-
-
-
-
r
nicotinamide + alpha-D-5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
nicotinamide clearance
NMN synthesis is rate-limiting step for NAD+ synthesis
-
r
nicotinamide + alpha-D-5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
DELTAG° = 1.1 kcal/mol, Keq = 0.15, unfavourable product-to-substrate ratio
equilibrium was established after 3 h in presence of 100 microM PRPP, 100 microM diphosphate, 5 microM nicotinamide mononucleotide, 0.6 microM NAMPT
-
r
nicotinamide + alpha-D-5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
whole cell lysates incubated with 5 microM [carbonyl-14C]nicotinamide + 0.5 mM alpha-D-5-phosphoribosyl-1-diphosphate at pH 8.8
produced NMN quantified by scintillation counting
-
r
nicotinamide + alpha-D-5-phosphoribosyl 1-diphosphate
nicotinamide mononucleotide + diphosphate
nicotinamide clearance
NMN synthesis is rate-limiting step for NAD+ synthesis
-
r
nicotinamide + alpha-D-5-phosphoribosyl-1-diphosphate
nicotinamide mononucleotide + diphosphate
-
-
-
r
nicotinamide + alpha-D-5-phosphoribosyl-1-diphosphate
nicotinamide mononucleotide + diphosphate
-
-
-
r
nicotinamide D-ribonucleotide + diphosphate
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
-
-
-
?
nicotinamide D-ribonucleotide + diphosphate
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
-
-
-
?
nicotinamide D-ribonucleotide + diphosphate
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
-
-
-
-
?
nicotinamide D-ribonucleotide + diphosphate
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
-
-
-
?
nicotinamide D-ribonucleotide + diphosphate
nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate
-
-
-
?
additional information
?
-
-
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis in tissues with a high demand for NAD+
-
-
?
additional information
?
-
NMPRTase is a crucial enzyme in the salvage pathway of NAD+ biosynthesis and has important functions in regulating NAD+ levels in cells undergoing substantial NAD+ turnover
-
-
?
additional information
?
-
-
NMPRTase is a crucial enzyme in the salvage pathway of NAD+ biosynthesis and has important functions in regulating NAD+ levels in cells undergoing substantial NAD+ turnover
-
-
?
additional information
?
-
-
rate-limiting enzyme for NAD+ salvage from nicotinamide. Replicative senescence of smooth muscle cells is preceded by a marked decline in the expression and activity of Nampt. Nampt is a longevity protein that can add stress-resistant life to human smooth muscle cells by optimizing SIRT1-mediated p53 degradation
-
-
?
additional information
?
-
rate-limiting enzyme for NAD+ salvage from nicotinamide. Replicative senescence of smooth muscle cells is preceded by a marked decline in the expression and activity of Nampt. Nampt is a longevity protein that can add stress-resistant life to human smooth muscle cells by optimizing SIRT1-mediated p53 degradation
-
-
?
additional information
?
-
facultative ATP hydrolysis activity, not tightly coupled to NMN synthesis
-
-
?
additional information
?
-
-
facultative ATP hydrolysis activity, not tightly coupled to NMN synthesis
-
-
?
additional information
?
-
the enzyme binds to the C-C chemokine receptor type 5 and acts as a natural antagonist of this receptor
-
-
-
additional information
?
-
pathway reconstitution in vitro using recombinant enzymes, overview
-
-
?
additional information
?
-
-
pathway reconstitution in vitro using recombinant enzymes, overview
-
-
?
additional information
?
-
NMPRTase is a crucial enzyme in the salvage pathway of NAD+ biosynthesis and has important functions in regulating NAD+ levels in cells undergoing substantial NAD+ turnover
-
-
?
additional information
?
-
-
NMPRTase is a crucial enzyme in the salvage pathway of NAD+ biosynthesis and has important functions in regulating NAD+ levels in cells undergoing substantial NAD+ turnover
-
-
?
additional information
?
-
the enzyme binds to the C-C chemokine receptor type 5 and acts as a natural antagonist of this receptor
-
-
-
additional information
?
-
visfatin mimics insulin signaling by binding to the insulin receptor with an affinity similar to that of insulin and does not share the binding site with insulin on the insulin receptor
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1Z)-N'-(benzoyloxy)-3-(2-oxo-1,3-benzoxazol-3(2H)-yl)propanimidamide
-
-
(2E)-1-(4-[[2-(4-fluorophenyl)-1,3-thiazol-4-yl]methyl]piperazin-1-yl)-3-(pyridin-3-yl)prop-2-en-1-one
-
(2E)-3-(6-aminopyridin-3-yl)-N-((5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl)methyl)prop-2-enamide
(2E)-3-(pyridin-3-yl)-1-[4-[4-(trifluoromethoxy)benzyl]piperazin-1-yl]prop-2-en-1-one
-
(2E)-3-(pyridin-3-yl)-N-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]prop-2-enamide
-
(2E)-3-(pyridin-3-yl)-N-[6-(3-[[4-(trifluoromethyl)phenyl]sulfamoyl]phenyl)hexyl]prop-2-enamide
-
(2E)-N-(6-[3-[(2,5-dimethylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(2-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
most potent inhibitor
(2E)-N-(6-[3-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(3-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-chlorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-ethylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-fluorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-phenoxyphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-(6-[3-[(4-tert-butylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[2-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-6-yl)oxy]ethyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[3-(1H-imidazol-1-yl)propyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[3-[3-(phenylsulfamoyl)phenyl]propyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[3-[4-(phenylsulfamoyl)phenyl]propyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
(2E)-N-[4-[4-(phenylsulfamoyl)phenyl]butyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[5-[3-(phenylsulfamoyl)phenyl]pentyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[5-[4-(phenylsulfamoyl)phenyl]pentyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[5-[4-([[2-(1H-indol-3-yl)ethyl](propan-2-yl)amino]methyl)anilino]pentyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[6-[3-(phenylsulfamoyl)phenyl]hexyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[6-[4-(phenylsulfamoyl)phenyl]hexyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[7-[3-(phenylsulfamoyl)phenyl]heptyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[7-[4-(phenylsulfamoyl)phenyl]heptyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2R,2'R)-5,5',7,7'-tetrahydroxy-2,2'-bis(4-hydroxyphenyl)-2,2',3,3'-tetrahydro-4H,4'H-[3,8'-bi-1-benzopyran]-4,4'-dione
-
-
(3R,5R,7R)-N-(4-((E)-3-(pyridin-3-yl)acrylamido)butyl)adamantane-1-carboxamide
-
(4',5,7-trihydroxyflavone)-(3'->8)-(4',5,7-trihydroxyflavone)
-
-
(4',7-dimethoxy-5-hydroxyflavone)-(3'->8)-(4',7-dimethoxy-5-hydroxyflavone)
-
-
(E)-N-(4-(1,12-dicarba-closo-dodecaboranyl)amidebutyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1,12-dicarba-closo-dodecaboranyl)amidepentyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1,7-dicarba-closo-dodecaboranyl)amidebutyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1-(1,12-dicarba-closo-dodecaboranyl)piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1-benzoyl-1,12-dicarba-closo-dodecaboran-12-yl)amidebutyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(1-trimethylsilyl-1,12-dicarba-closododecaboran-12-yl)amidebutyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranecarbonyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranecarbonyl)-1,7-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranyl(hydroxy)methyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
-
(E)-N-(4-(4-(1,7-dicarba-closo-dodecaboranecarbonyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
-
1,1-dioxo-N-[[4-[(4-pyrrolidin-1-yl-1-piperidyl)sulfonyl]-phenyl]methyl]-2H-pyrido[4,3-e][1,2,4]thiadiazin-3-amine
-
1-((E)-4-(3-(pyridin-3-yl)acrylamido)hexyl)-1,12-dicarba-closo-dodecaborane
-
1-((E)-4-(3-(pyridin-3-yl)acrylamido)hexyl)-1,2-dicarba-closo-dodecaborane
-
1-((E)-4-(3-(pyridin-3-yl)acrylamido)pentyl)-1,2-dicarba-closo-dodecaborane
-
1-(4-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)butyl)-1,2-dicarba-closo-dodecaborane
-
1-(4-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)pentyl)-1,2-dicarba-closo-dodecaborane
-
1-(5-(1H-pyrrolo[3,2-c]pyridine-2-carboxamido)butyl)-1,2-dicarba-closo-dodecaborane
-
1-(5-(1H-pyrrolo[3,2-c]pyridine-2-carboxamido)pentyl)-1,2-dicarba-closo-dodecaborane
-
1-(pyridin-3-ylmethyl)-3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]thiourea
-
-
1-([1,1'-biphenyl]-2-yl)-3-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)urea
-
1-methyl-N-[4-(phenylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
1-[(6-aminopyridin-3-yl)methyl]-3-[4-(phenylsulfonyl)phenyl]urea
-
1-[2-(naphthalen-2-yloxy)ethyl]-3-(pyridin-3-ylmethyl)urea
-
1-[3-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
-
potent inhibitor
1-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
-
1-[4-(morpholin-4-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
-
-
1-[4-(piperazin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
-
-
1-[4-(piperidin-1-ylcarbonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
-
-
1-[4-(piperidin-1-yloxy)phenyl]-3-(pyridin-3-ylmethyl)guanidine
-
-
1-[4-(piperidin-1-yloxy)phenyl]-3-(pyridin-3-ylmethyl)urea
-
-
1-[4-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)guanidine
-
-
1-[4-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
-
-
1-[4-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-4-ylmethyl)thiourea
-
-
1-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-3-(pyridin-3-ylmethyl)thiourea
-
-
1H-indol-2-yl(4-[[3-(pyridin-3-yl)-1H-pyrazol-5-yl]carbonyl]piperazin-1-yl)methanone
-
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-2-carboxylic acid
-
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-3-carboxylic acid
-
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-4-carboxylic acid
-
2'-methyl-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
-
2'-[(aminooxy)carbonyl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
-
2-(4-[[4-(1-ethoxyethenyl)piperidin-1-yl]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-(4-[[4-(propan-2-yl)piperazin-1-yl]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl [1,1'-biphenyl]-2-ylcarbamate
-
2-(4-[[bis(2-hydroxyethyl)amino]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-(pyridin-3-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-bromo-N-[2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl]benzene-1-sulfonamide
-
2-cyano-1-[4-(phenylsulfonyl)benzyl]-3-pyridin-4-ylguanidine
-
2-[4-[(4-chlorophenyl)sulfamoyl]phenoxy]-N-(pyridin-3-ylmethyl)acetamide
-
2-[4-[(4-hydroxypiperidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-[4-[(4-methylpiperazin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
inhibitor of the extracellular enzyme form
2-[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-[4-[(morpholin-4-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
2-[4-[(piperidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
-
3-(1-(4-(2-([1,1'-biphenyl]-2-yloxy)ethyl)benzyl)-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-(6-([1,1'-biphenyl]-2-yloxy)hexyl)-1H-1,2,3-triazol-4-yl)-pyridine
-
3-(1-(7-(4-([1,1'-biphenyl]-2-yl)-1H-1,2,3-triazol-1-yl)-heptyl)-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-(7-([1,1'-biphenyl]-2-yloxy)heptyl)-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-(8-([1,1'-biphenyl]-2-yloxy)octyl)-1H-1,2,3-triazol-4-yl)-pyridine
-
3-(1-[6-[(2'-methyl[1,1'-biphenyl]-2-yl)oxy]hexyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[6-[([1,1'-biphenyl]-2-yl)oxy]hexyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[6-[2-(pyridin-3-yl)phenoxy]hexyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[7-[([1,1'-biphenyl]-2-yl)oxy]heptyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[7-[4-([1,1'-biphenyl]-2-yl)-1H-1,2,3-triazol-1-yl]heptyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-(1-[8-[([1,1'-biphenyl]-2-yl)oxy]octyl]-1H-1,2,3-triazol-4-yl)pyridine
-
3-acetylpyridine
-
weak, kinetics
3-acetylpyridine adenine dinucleotide
-
kinetics
3-[1-[(4-[2-[([1,1'-biphenyl]-2-yl)oxy]ethyl]phenyl)methyl]-1H-1,2,3-triazol-4-yl]pyridine
-
4-chloro-N-[(5-[[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]sulfamoyl]thiophen-2-yl)methyl]benzamide
-
-
4-chloro-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
4-[([7-chloro-3-methyl-2-[(4-methylpiperazin-1-yl)methyl]-4-oxo-3,4-dihydroquinazolin-6-yl]methyl)(prop-2-yn-1-yl)amino]-N-[(pyridin-3-yl)methyl]benzamide
-
4-[[(2E)-3-(pyridin-3-yl)prop-2-enoyl]amino]-N-(2,2,2-trifluoroethyl)benzamide
-
4-[[(3,7-dimethyl-4-oxo-3,4-dihydro-1,2,3-benzotriazin-6-yl)methyl](3-methylbut-2-en-1-yl)amino]-N-[(pyridin-3-yl)methyl]benzamide
-
4-[[(4-tert-butylbenzene-1-sulfonyl)amino]methyl]-N-(pyridin-3-yl)benzamide
-
5,6-dimethoxy-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-(3,4-dichlorobenzyl)-4-oxo-N-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamide
-
5-(hydroxymethyl)-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-chloro-N-(4-[1-[(2S)-oxolane-2-carbonyl]piperidin-4-yl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-cyano-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-fluoro-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-fluoro-N-[4-[1-(1-methylpiperidine-4-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-fluoro-N-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-Fluoronicotinamide
-
weak, kinetics
5-methoxy-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5-methyl-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
5P-DADMe-NMN
poor, competitive inhibitor of non-ATP and ATP coupled NMN synthesis with respect to PRPP and nicotinamide, 3-fold increased binding in presence of ATP
6-aminonicotinamide
-
weak, kinetics
6-[(benzylcarbamoyl)amino]-N-cyclohexyl-N-[2-(morpholin-4-yl)ethoxy]hexane-1-sulfonamide
-
6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexyl [1,1'-biphenyl]-2-ylcarbamate
-
7-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)heptyl [1,1'-biphenyl]-2-ylcarbamate
-
7-chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
-
alpha-D-5-phosphoribosyl 1-diphosphate
inhibits ATPase activity at 1 mM concentration, nearly complete inhibition of ADP-ATP exchange at 100 microM
CHS-828
competitive inhibitor
ethyl [(E)-[4-(piperidine-1-sulfonyl)anilino][[(pyridin-3-yl)methyl]amino]methylidene]carbamate
-
-
gallotanine
-
i.e. (2R,3S,5R,6S)-tetrahydro-2H-pyran-2,3,4,5,6-pentaylpentakis(oxycarbonyl-5,6-dihydroxybenzene-3,1-diyl) pentakis(3,4,5-trihydroxybenzoate)
hypoxanthine
-
phosphorolysis
methyl 4-[(1,3-dihydro-2H-isoindole-2-carbonyl)amino]benzoate
-
N''-cyano-N-([4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl]methyl)-N'-pyridin-4-ylguanidine
-
N''-cyano-N-pyridin-4-yl-N'-([4-[3-(trifluoromethoxy)benzene-1-sulfonyl]phenyl]methyl)guanidine
-
N''-cyano-N-pyridin-4-yl-N'-([4-[3-(trifluoromethyl)benzene-1-sulfonyl]phenyl]methyl)guanidine
-
N''-cyano-N-pyridin-4-yl-N'-[[4-(quinoline-8-sulfonyl)phenyl]methyl]guanidine
-
N''-cyano-N-[[4-(3,5-difluorobenzene-1-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(3-methoxybenzene-1-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)phenyl]methyl]-N'-pyridin-3-ylguanidine
-
N''-cyano-N-[[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(cyclohexanesulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(phenylmethanesulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N''-cyano-N-[[4-(pyridine-3-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
-
N-(2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-oxoethyl)-3-methylthiophene-2-carboxamide
-
N-(2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-oxoethyl)-5-methylthiophene-2-carboxamide
-
N-(4-butylphenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
N-(4-carbamoylphenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-methylphenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[1-[2-methyl-2-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-yl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[3-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]propyl]phenyl)[1,1'-biphenyl]-2-carboxamide
-
N-(4-[4-[(1H-benzimidazol-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(2,6-difluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(2-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(2-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(2-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(3-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(3-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(3-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-aminophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-bromophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-butylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(4-nitrophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(furan-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(furan-3-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[4-[(naphthalen-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-(4-[[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[[(oxan-3-yl)methyl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[[(oxolan-3-yl)methyl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[[1-(2-methylbutanoyl)piperidin-4-yl]oxy]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-(4-[[1-(propan-2-yl)-1H-pyrazol-4-yl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(4-[[3-(trifluoromethoxy)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
N-(4-[[4-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(4-[[5-(trifluoromethyl)pyridin-3-yl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide
-
N-(7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl)[1,1'-biphenyl]-2-carboxamide
MV78
N-(8-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)octyl)biphenyl-2-sulfonamide
-
N-(pyridin-4-yl)cyclopropanecarboxamide
-
N-([1,1'-biphenyl]-2-yl)-8-(2-(pyridin-3-yl)thiazol-5-yl)-octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)-octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl)octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)isoxazol-3-yl)-octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octanamide
N-([4-(3,5-difluorobenzene-1-sulfonyl)phenyl]methyl)imidazo[1,2-a]pyridine-6-carboxamide
GNE-617
N-([4-[(3,5-difluorophenyl)methyl]phenyl]methyl)imidazo[1,2-a]pyridine-6-carboxamide
-
N-([4-[1-(oxan-4-yl)piperidine-4-sulfonyl]phenyl]methyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
-
N-([4-[4-(oxetan-3-yl)piperazine-1-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-([4-[4-(pyrrolidin-1-yl)piperidine-1-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-([4-[6-(dimethylamino)pyridine-3-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-([4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-benzyl-4-[[(pyridin-3-ylmethyl)carbamothioyl]amino]benzenesulfonamide
-
-
N-biphenyl-2-yl-8-(4-pyridin-3-yl-1H-1,2,3-triazol-1-yl)octanamide
displays an IC50 for cytotoxicity in vitro of 3.8 nM and an IC50 for NAD depletion of 3.0 nM. Compound induces autophagic cell death
-
N-phenyl-4-[[(pyridin-3-ylmethyl)carbamothioyl]amino]benzenesulfonamide
-
-
N-[(5-[[3-(trifluoromethyl)phenyl]sulfonyl]pyridin-2-yl)methyl]furo[2,3-c]pyridine-2-carboxamide
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(pyridin-3-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(pyridin-4-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(thiophen-2-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(thiophen-3-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-[4-(4-[[4-(trifluoromethoxy)phenyl]methyl]piperazine-1-sulfonyl)phenyl]thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-[4-(4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-sulfonyl)phenyl]thiourea
-
-
N-[(pyridin-3-yl)methyl]-N'-[4-[4-(pyridin-2-yl)piperazine-1-sulfonyl]phenyl]thiourea
-
-
N-[([1,1'-biphenyl]-2-yl)methyl]-2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethan-1-amine
-
N-[1,1'-biphenyl]-2-yl-N'-[2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl]urea
-
N-[1,1'-biphenyl]-2-yl-N'-[6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexyl]urea
-
N-[1,1'-biphenyl]-2-yl-N'-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]urea
-
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-benzofuran-2-carboxamide
-
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-benzothiophene-2-carboxamide
N-[2-(3,4-dimethoxyphenyl)ethyl]-3-methylthiophene-2-carboxamide
-
N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methylthiophene-2-carboxamide
-
N-[2-(3,4-dimethoxyphenyl)ethyl]-5-nitrothiophene-2-carboxamide
-
N-[2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl][1,1'-biphenyl]-2-carboxamide
-
N-[2-(4-[[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]methyl]phenyl)ethyl][1,1'-biphenyl]-2-sulfonamide
-
N-[2-chloro-5-(trifluoromethyl)phenyl]-4-([[(pyridin-3-yl)methyl]carbamoyl]amino)benzene-1-sulfonamide
-
N-[3-(1H-imidazol-1-yl)propyl]-1-benzofuran-2-carboxamide
-
N-[3-(1H-imidazol-1-yl)propyl]-1-benzothiophene-2-carboxamide
-
N-[3-(1H-imidazol-1-yl)propyl]-3-methylthiophene-2-carboxamide
-
N-[3-(1H-imidazol-1-yl)propyl]-5-methylthiophene-2-carboxamide
-
N-[3-(1H-imidazol-1-yl)propyl]-5-nitrothiophene-2-carboxamide
-
N-[3-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-benzoylazetidin-3-yl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(1-propyl-1H-pyrazole-3-sulfonyl)phenyl]-2-(pyridin-3-yl)cyclopropane-1-carboxamide
-
N-[4-(4-acetylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(4-benzylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-[4-(4-cyclohexylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]urea
-
N-[4-(benzenesulfonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(benzenesulfonyl)phenyl]-2-(pyridin-3-yl)cyclopropane-1-carboxamide
-
N-[4-(benzylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(morpholin-4-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-(phenylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-(phenylsulfonyl)benzyl]-1H-pyrazolo[3,4-c]pyridine-5-carboxamide
-
N-[4-(phenylsulfonyl)benzyl]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
-
N-[4-(phenylsulfonyl)benzyl]-1H-pyrrolo[3,2-c]pyridine-2-carboxamide
-
N-[4-(phenylsulfonyl)benzyl]-5-(pyridin-3-yl)-1H-pyrazole-3-carboxamide
-
N-[4-(phenylsulfonyl)benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[4-(piperidin-1-ylsulfonyl)benzyl]-1H-indazole-5-carboxamide
-
N-[4-(piperidin-1-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-(piperidin-1-ylsulfonyl)benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-(quinolin-3-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-([[(3S)-oxolan-3-yl]methyl]carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(1-ethyl-1H-pyrazol-4-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(1-propyl-1H-pyrazol-4-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(3,3-dimethylbutyl)(methyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3,3-dimethylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]imidazo[1,2-a]pyridine-6-carboxamide
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
-
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3-methylbutyl)sulfamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(3-phenylpropyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(4-cyanopiperidin-1-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(4-hydroxypiperidin-1-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(4-methylpentanoyl)amino]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[(4E)-4-(2,3-dimethoxybenzylidene)-5-oxo-4,5-dihydro-1,3-oxazol-2-yl]phenyl]thiophene-2-carboxamide
-
-
N-[4-[(5-chloropyridin-3-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[4-[(6-methylpyridin-3-yl)sulfonyl]benzyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
-
N-[4-[1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(3-hydroxy-3-methylbutanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(3-methyloxetane-3-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[1-(cyclopropanesulfonyl)piperidin-4-yl]phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[4-[4-(4-methylphenyl)piperazine-1-sulfonyl]phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
-
-
N-[4-[4-(pyridin-2-yl)piperazine-1-carbonyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[5-[(3-methylbutyl)carbamoyl]pyridin-2-yl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-phenylguanidine
N-[6-[(3-methylbutyl)carbamoyl]pyridin-3-yl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexyl][1,1'-biphenyl]-2-carboxamide
-
N-[7-[4-(1-oxo-1lambda(5)-pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
-
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-(1H-1,2,3-triazol-1-yl)benzamide
inhibitor of the intracellular enzyme form
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-(1H-1,2,3-triazol-4-yl)benzamide
-
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-[4-[(pyrrolidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]benzamide
-
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
-
N-[8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octyl][1,1'-biphenyl]-2-sulfonamide
-
N-[[4-(3,5-difluorobenzene-1-sulfonyl)phenyl]methyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[[4-(4-aminopiperidine-1-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[[4-(4-methoxypiperidine-1-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[[4-(6-methylpyridine-3-sulfonyl)phenyl]methyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
-
N-[[4-(7-oxa-2-azaspiro[3.5]nonane-2-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-[[4-(benzenesulfonyl)phenyl]methyl]-1,1-dioxo-2H-pyrido[4,3-e][1,2,4]thiadiazin-3-amine
-
N-[[4-(benzenesulfonyl)phenyl]methyl]-1,3-dihydro-2H-isoindole-2-carboxamide
-
N-[[4-(benzenesulfonyl)phenyl]methyl]-1H-pyrazolo[4,3-b]pyridine-5-carboxamide
-
N-[[4-(benzenesulfonyl)phenyl]methyl]-N''-cyano-N'-pyridin-3-ylguanidine
-
nicotinamide
substrate inhibition
nicotinamide hypoxanthine dinucleotide
-
-
nicotinamide mononucleotide
-
kinetics
nicotinamide mononucleotide-H2
-
strong, kinetics
nicotinamide riboside
-
kinetics
nicotinate adenine dinucleotide
teglarinad
water soluble pro-drug of N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-phenylguanidine (CHS828)
tert-butyl ((1,12-dicarba-closo-dodecaboranylamido)propyl)carbamate
-
tert-butyl 4-[4-([[(pyridin-3-yl)methyl]carbamothioyl]amino)benzene-1-sulfonyl]piperazine-1-carboxylate
-
-
tert-butyl trans-1-(2-(pyridin-3-yl)cyclopropanecarbonyl)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate
-
tert-butyl trans-6-(2-(pyridin-3-yl)cyclopropanecarbonyl)-2,6-diazaspiro[3.4]octane-2-carboxylate
-
Thionicotinamide
-
weak, kinetics
Thionicotinamide adenine dinucleotide
-
-
TP201565
competitive inhibitor
trans-(R,R)-N-(4-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-(S,S)-N-(4-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-(S,S)-N-(4-((1-propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
potent inhibitor
trans-2-(6-aminopyridin-3-yl)-N-(4-(phenylsulfonyl)benzyl)-cyclopropanecarboxamide
-
trans-2-(6-aminopyridin-3-yl)-N-(4-(phenylsulfonyl)phenyl)-cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((3-(trifluoromethoxy)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((3-(trifluoromethyl)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-(pyridin-3-yl)-N-(4-((tetrahydro-2H-pyran-4-yl)-sulfonyl)phenyl)cyclopropanecarboxamide
-
trans-2-phenyl-N-(pyridin-4-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-(2-Hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)-sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-ethyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-isopropyl-3-methyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-isopropyl-5-methyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((1-propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((3,5-difluorophenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((3-(methylsulfonyl)phenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-((6-methylpyridin-3-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-(1-benzoylpiperidin-4-yl)butyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
trans-N-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-ylsulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
-
trans-N-(4-(morpholinosulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
trans-N-(4-(phenylsulfonyl)benzyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
trans-N-(4-(phenylsulfonyl)benzyl)-2-(pyridin-4-yl)-cyclopropanecarboxamide
-
trans-N-(4-(phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
trans-N-(4-(phenylsulfonyl)phenyl)-2-(pyridin-4-yl)-cyclopropanecarboxamide
-
trans-N-(6-(4-chlorophenoxy)hexyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
-
[4-(diphenylmethyl)piperazin-1-yl][5-(pyridin-3-yl)-1H-pyrazol-3-yl]methanone
-
(2E)-3-(6-aminopyridin-3-yl)-N-((5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl)methyl)prop-2-enamide
KPT-9274
(2E)-3-(6-aminopyridin-3-yl)-N-((5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl)methyl)prop-2-enamide
KPT-9274
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
-
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
FK866
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
FK866, potent inhibitor
APO866
also known as FK866, (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridine-3-yl)-acrylamide, no impact on cell viability, dose-dependent reduction of levels of intracellular NAD in and secretion of TNFalpha, IL-1beta, IL-6 (pro-inflammatory cytokines) by monocyctes, monocyte-derived dendritic cells and total PBMCs upon stimulation of inflammatory response by 100 ng/ml lipopolysaccharide (LPS) or 5 microgram/ml Pansorbin (Staphylococcus aureus cells, SAC)
APO866
also known as FK866, (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridine-3-yl)-acrylamide, 10 mg/kg, DBA/1 mice: beneficial effects on collagen-induced arthritis (CIA) due to impaired secretion of inflammatory cytokines (reduction of the mean arthritic score and number of affected paws from mice with CIA as well as decrease in local levels of IL-1beta and IL-6 but no impact on IL-10, IFN-gamma, CCL5 and IL-12p70 levels, decrease in inflammatory infiltrate and hyperplasia in knees and paws from mice with CIA) but not due to toxicity (no premature death of individuals, no impact on histology of liver, spleen, lung, gut, kidney, inguinal lymph nodes and brain, normal liver alanine aminotransferase levels, no enhanced apoptosis in arthritic paws) and not due to impact on anti-collagen immune response (similar anti-collagen IgG levels); also known as FK866, (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridine-3-yl)-acrylamide, 10 mg/kg, isolated peritoneal exudate inflammatory cells (PEC) from C57BL/6 mice: time-dependent NAD depletion (lowest at 9 h, recovery after 14 h), addition of 10 mM NMN abolishes a reduction of intracellular NAD+ concentration as well as TNFalpha and IL-6 secretion (pro-inflammatory cytokines) in PECs induced by in vivo or in vitro stimulation of inflammatory response with 5 microgram/ml Pansorbin (Staphylococcus aureus cells, SAC) or 100 ng/ml lipopolysaccharide (LPS)
CHS828
-
CHS828
also known as GMX1778
FK-866
-
FK-866
-
i.e. (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-phenylprop-2-enamide
FK-866
i.e. (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-phenylprop-2-enamide
FK-866
-
i.e. (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-phenylprop-2-enamide
FK-866
-
i.e. (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-phenylprop-2-enamide
FK-866
the nicotinamide-binding site is important for inhibition by FK-866
FK866
-
a highly specific noncompetitive inhibitor the enzyme, represents a novel mechanism for induction of tumor cell apoptosis, counteracted by nicotinic acid and nicotinamide
FK866
Nampt antagonist, 10 nM, reduction of Nampt activity in SMCs to 22 +/-2% of baseline activity accompanied with shortened senescent-free survival; reducing Nampt activity with the antagonist FK866 induces premature senescence in smooth muscle cells
FK866
FK866 is bound in a tunnel at the interface of the NMPRTase dimer, the inhibitor can reduce cellular NAD+ levels and induce apoptosis in tumors
FK866
powerful, non-competitive inhibitor with and without ATP
FK866
i.e. daporinad, (E)-N-[4-[1-(benzoyl)piperidin-4-yl]butyl]-3-pyridin-3-ylprop-2-enamide
FK866
potent competitive inhibitor
FK866
specific and potent inhibitor
FK866
i.e. (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
FK866
selective inhibitor
FK866
FK866 is bound in a tunnel at the interface of the NMPRTase dimer, the inhibitor can reduce cellular NAD+ levels and induce apoptosis in tumors
GMX-1778
-
GMX-1778
i.e. (E)-1-(6-(4-chlorophenoxy)hexyl)-2-cyano-3-(pyridin-4-yl)-guanidine
GMX-1778
formerly CHS-828
GMX-1778
formerly CHS-828
GMX1777
-
i.e. 1-[2-(2-(2-(2-methoxyethoxy)-ethoxy)ethoxy)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chlorophenyl)-hexyl)-N-guanidino]pyridinium chloride, prodrug of GMX1778. A dose of 75 mg/kg administered over a 24 h intravenous infusion causes tumor regression in the IM-9 model, the SHP-77 model, and HCT-116 model. A 72 h continuous intravenous infusion is also effective in the IM-9 model, but is associated with smaller therapeutic index
GMX1777
-
i.e. 1-[2-(2-(2-(2-methoxyethoxy)-ethoxy)ethoxy)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chlorophenyl)-hexyl)-N-guanidino]pyridinium chloride, prodrug of GMX1778. A dose of 75 mg/kg administered over a 24 h intravenous infusion produces GMX1778 steady-state plasma levels of about 1 microg/ml and causes nicotinamide dinucleotide levels to decrease significnantly in tumors. Nicotinic acid protects mice treated with a lethal dose of GMX1777
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
-
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
-
N-([1,1'-biphenyl]-2-yl)-8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octanamide
-
N-([1,1'-biphenyl]-2-yl)-8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octanamide
GPP78
N-([1,1'-biphenyl]-2-yl)-8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octanamide
GPP78
N-[(5-[[3-(trifluoromethyl)phenyl]sulfonyl]pyridin-2-yl)methyl]furo[2,3-c]pyridine-2-carboxamide
-
N-[(5-[[3-(trifluoromethyl)phenyl]sulfonyl]pyridin-2-yl)methyl]furo[2,3-c]pyridine-2-carboxamide
-
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-benzothiophene-2-carboxamide
-
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-benzothiophene-2-carboxamide
-
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
-
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]imidazo[1,2-a]pyridine-6-carboxamide
-
N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-phenylguanidine
CHS828
N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-phenylguanidine
CHS828, potent inhibitor
NAD+
-
-
NAD+
competitive inhibitor of non-ATP and ATP coupled NMN synthesis with respect to PRPP and nicotinamide
NAD+
-
1 mM, 50%-90% inhibition in various tissues, at 0.2 mM not inhibitory in lung and liver; strong (thigh muscle)
NADH
competitive inhibitor of non-ATP and ATP coupled NMN synthesis with respect to PRPP and nicotinamide
nicotinate adenine dinucleotide
-
not inhibitory
nicotinate adenine dinucleotide
-
weak
additional information
-
no inhibition by NaF
-
additional information
-
nicotinic acid, thymine, 5-bromouracil
-
additional information
no impact on ADP-ATP exchange rate by 10 microM adenylate kinase inhibitor P(1), P(5)-di(adenosine-5-)pentaphosphate (Ap5A), NAMPT does not accommodate Ap5A
-
additional information
-
no impact on ADP-ATP exchange rate by 10 microM adenylate kinase inhibitor P(1), P(5)-di(adenosine-5-)pentaphosphate (Ap5A), NAMPT does not accommodate Ap5A
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000017
4-chloro-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.009
5,6-dimethoxy-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Ki above 0.009 mM, pH and temperature not specified in the publication
0.0000049
5-(hydroxymethyl)-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000017
5-chloro-N-(4-[1-[(2S)-oxolane-2-carbonyl]piperidin-4-yl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000047
5-cyano-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000079
5-fluoro-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000094
5-fluoro-N-[4-[1-(1-methylpiperidine-4-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000025
5-fluoro-N-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000016
5-methoxy-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000013
5-methyl-N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.00016 - 0.0071
5P-DADMe-NMN
0.000003
GMX1778
pH and temperature not specified in the publication
0.000112
methyl 4-[(1,3-dihydro-2H-isoindole-2-carbonyl)amino]benzoate
pH and temperature not specified in the publication
0.00056
N-(4-carbamoylphenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0022
N-(4-methylphenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000015
N-(4-[1-[2-methyl-2-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-yl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000019
N-(4-[[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000013
N-(4-[[(oxan-3-yl)methyl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000024
N-(4-[[(oxolan-3-yl)methyl]carbamoyl]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000018
N-(4-[[1-(2-methylbutanoyl)piperidin-4-yl]oxy]phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0089
N-[3-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Ki above 0.0089 mM, pH and temperature not specified in the publication
0.000003
N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000019
N-[4-(1-benzoylazetidin-3-yl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000016
N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000001
N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000019
N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000021
N-[4-(benzenesulfonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000019
N-[4-(benzylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000104
N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.00016
N-[4-[(3,3-dimethylbutyl)(methyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000014
N-[4-[(3,3-dimethylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000011
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000075
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
pH and temperature not specified in the publication
0.000023
N-[4-[(3-methylbutyl)carbamoyl]phenyl]-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.00035
N-[4-[(3-methylbutyl)sulfamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000009
N-[4-[(3-phenylpropyl)carbamoyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000058
N-[4-[(4-methylpentanoyl)amino]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000043
N-[4-[1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000015
N-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000056
N-[4-[1-(3-hydroxy-3-methylbutanoyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000023
N-[4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000051
N-[4-[1-(3-methyloxetane-3-carbonyl)piperidin-4-yl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000039
N-[4-[1-(cyclopropanesulfonyl)piperidin-4-yl]phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000014
N-[4-[4-(pyridin-2-yl)piperazine-1-carbonyl]phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.0000054
N-[5-[(3-methylbutyl)carbamoyl]pyridin-2-yl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000057
N-[6-[(3-methylbutyl)carbamoyl]pyridin-3-yl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.000487
N-[[4-(benzenesulfonyl)phenyl]methyl]-1,3-dihydro-2H-isoindole-2-carboxamide
pH and temperature not specified in the publication
0.00025 - 0.003
nicotinamide
additional information
ATP
0.00016
5P-DADMe-NMN
with respect to alpha-D-5-phosphoribosyl 1-diphosphate (PRPP), in presence of 2.5 mM ATP, KM/Ki = 4, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
0.00053
5P-DADMe-NMN
with respect to alpha-D-5-phosphoribosyl 1-diphosphate (PRPP), in absence of ATP, KM/Ki = 14, 100 microM PRPP, 1 microM nicotinamide, 88 nM NAMPT, 15 min
0.0025
5P-DADMe-NMN
with respect to nicotinamide, in presence of 2.5 mM ATP, KM/Ki <1, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
0.0071
5P-DADMe-NMN
with respect to nicotinamide, in absence of ATP, KM/Ki <1, 100 microM PRPP, 1 microM nicotinamide, 88 nM NAMPT, 15 min
0.000003
FK866
pH and temperature not specified in the publication
0.0003
FK866
-
free enzyme
0.0004
FK866
-
enzyme-substrate complex
0.00014
NAD+
with respect to alpha-D-5-phosphoribosyl 1-diphosphate (PRPP), in presence of 2.5 mM ATP, KM/Ki = 5, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
0.0021
NAD+
with respect to nicotinamide, in presence of 2.5 mM ATP, KM/Ki <1, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
0.00022
NADH
with respect to alpha-D-5-phosphoribosyl 1-diphosphate (PRPP), in presence of 2.5 mM ATP, KM/Ki = 3, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
0.0032
NADH
with respect to nicotinamide, in presence of 2.5 mM ATP, KM/Ki <1, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
0.00025
nicotinamide
NMN synthesis
0.003
nicotinamide
NMN synthesis, in presence of 5 microM NAD+
additional information
ATP
> 4 mM, inhibition of NMN synthesis by phosphorylated NAMPT
additional information
ATP
-
> 4 mM, inhibition of NMN synthesis by phosphorylated NAMPT
additional information
FK866
10 +/-1 pM, with respect to alpha-D-5-phosphoribosyl 1-diphosphate (PRPP), in presence of 2.5 mM ATP, KM/Ki = 63000, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
additional information
FK866
-
10 +/-1 pM, with respect to alpha-D-5-phosphoribosyl 1-diphosphate (PRPP), in presence of 2.5 mM ATP, KM/Ki = 63000, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
additional information
FK866
150 +/-18 pM, with respect to nicotinamide, in presence of 2.5 mM ATP, KM/Ki = 33, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
additional information
FK866
-
150 +/-18 pM, with respect to nicotinamide, in presence of 2.5 mM ATP, KM/Ki = 33, 200 microM PRPP, 100 nM nicotinamide, 2.2 nM NAMPT, 15 min
additional information
FK866
5000 +/-500 pM, with respect to nicotinamide, in absence of ATP, KM/Ki = 171, 100 microM PRPP, 1 microM nicotinamide, 88 nM NAMPT, 15 min
additional information
FK866
-
5000 +/-500 pM, with respect to nicotinamide, in absence of ATP, KM/Ki = 171, 100 microM PRPP, 1 microM nicotinamide, 88 nM NAMPT, 15 min
additional information
FK866
730 +/-75 pM, with respect to alpha-D-5-phosphoribosyl 1-diphosphate (PRPP), in absence of ATP, KM/Ki = 9863, 100 microM PRPP, 1 microM nicotinamide, 88 nM NAMPT, 15 min
additional information
FK866
-
730 +/-75 pM, with respect to alpha-D-5-phosphoribosyl 1-diphosphate (PRPP), in absence of ATP, KM/Ki = 9863, 100 microM PRPP, 1 microM nicotinamide, 88 nM NAMPT, 15 min
additional information
NAD+
> 100 microM, with respect to nicotinamide, in absence of ATP
additional information
NAD+
-
> 100 microM, with respect to nicotinamide, in absence of ATP
additional information
NADH
> 100 microM, with respect to nicotinamide, in absence of ATP
additional information
NADH
-
> 100 microM, with respect to nicotinamide, in absence of ATP
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.855
(1Z)-N'-(benzoyloxy)-3-(2-oxo-1,3-benzoxazol-3(2H)-yl)propanimidamide
Homo sapiens
-
at pH 7.5 and 37°C
0.0032
(2E)-1-(4-[[2-(4-fluorophenyl)-1,3-thiazol-4-yl]methyl]piperazin-1-yl)-3-(pyridin-3-yl)prop-2-en-1-one
Homo sapiens
pH and temperature not specified in the publication
0.00078
(2E)-3-(pyridin-3-yl)-1-[4-[4-(trifluoromethoxy)benzyl]piperazin-1-yl]prop-2-en-1-one
Homo sapiens
pH and temperature not specified in the publication
0.00067
(2E)-3-(pyridin-3-yl)-N-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00002453
(2E)-3-(pyridin-3-yl)-N-[6-(3-[[4-(trifluoromethyl)phenyl]sulfamoyl]phenyl)hexyl]prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00001163
(2E)-N-(6-[3-[(2,5-dimethylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00000508
(2E)-N-(6-[3-[(2-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.0000097
(2E)-N-(6-[3-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00001228
(2E)-N-(6-[3-[(3-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00001075
(2E)-N-(6-[3-[(4-chlorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00003154
(2E)-N-(6-[3-[(4-ethylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.0000092
(2E)-N-(6-[3-[(4-fluorophenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00000978
(2E)-N-(6-[3-[(4-methylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00001309
(2E)-N-(6-[3-[(4-phenoxyphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00000947
(2E)-N-(6-[3-[(4-tert-butylphenyl)sulfamoyl]phenyl]hexyl)-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.01
(2E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00094
(2E)-N-[2-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-6-yl)oxy]ethyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.01
(2E)-N-[3-(1H-imidazol-1-yl)propyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.0002345
(2E)-N-[3-[3-(phenylsulfamoyl)phenyl]propyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00592
(2E)-N-[3-[4-(phenylsulfamoyl)phenyl]propyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.0000027 - 0.0000049
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
0.00001777
(2E)-N-[4-[4-(phenylsulfamoyl)phenyl]butyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00001654
(2E)-N-[5-[3-(phenylsulfamoyl)phenyl]pentyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00002839
(2E)-N-[5-[4-(phenylsulfamoyl)phenyl]pentyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00001053
(2E)-N-[6-[3-(phenylsulfamoyl)phenyl]hexyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00001442
(2E)-N-[6-[4-(phenylsulfamoyl)phenyl]hexyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00003132
(2E)-N-[7-[3-(phenylsulfamoyl)phenyl]heptyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.00001641
(2E)-N-[7-[4-(phenylsulfamoyl)phenyl]heptyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.504
(2R,2'R)-5,5',7,7'-tetrahydroxy-2,2'-bis(4-hydroxyphenyl)-2,2',3,3'-tetrahydro-4H,4'H-[3,8'-bi-1-benzopyran]-4,4'-dione
Homo sapiens
-
at pH 7.5 and 37°C
0.008
(3R,5R,7R)-N-(4-((E)-3-(pyridin-3-yl)acrylamido)butyl)adamantane-1-carboxamide
Homo sapiens
at 30°C, pH not specified in the publication
0.0066
(4',5,7-trihydroxyflavone)-(3'->8)-(4',5,7-trihydroxyflavone)
Mus musculus
-
pH 7.5, 37°C
0.0175
(4',7-dimethoxy-5-hydroxyflavone)-(3'->8)-(4',7-dimethoxy-5-hydroxyflavone)
Mus musculus
-
pH 7.5, 37°C
0.000057
(E)-N-(4-(1,12-dicarba-closo-dodecaboranyl)amidebutyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.00017
(E)-N-(4-(1,12-dicarba-closo-dodecaboranyl)amidepentyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.000098
(E)-N-(4-(1,7-dicarba-closo-dodecaboranyl)amidebutyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.00032
(E)-N-(4-(1-(1,12-dicarba-closo-dodecaboranyl)piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.00063
(E)-N-(4-(1-benzoyl-1,12-dicarba-closo-dodecaboran-12-yl)amidebutyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.00018
(E)-N-(4-(1-trimethylsilyl-1,12-dicarba-closododecaboran-12-yl)amidebutyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.01
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranecarbonyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
IC50 above 0.01 mM, at 30°C, pH not specified in the publication
0.00292
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranecarbonyl)-1,7-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.00451
(E)-N-(4-(4-(1,12-dicarba-closo-dodecaboranyl(hydroxy)methyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.00376
(E)-N-(4-(4-(1,7-dicarba-closo-dodecaboranecarbonyl)-1,12-dicarba-closo-dodecaboranyl)butyl)-3-(pyridin-3-yl)acrylamide
Homo sapiens
at 30°C, pH not specified in the publication
0.000062
1,1-dioxo-N-[[4-[(4-pyrrolidin-1-yl-1-piperidyl)sulfonyl]-phenyl]methyl]-2H-pyrido[4,3-e][1,2,4]thiadiazin-3-amine
Homo sapiens
pH and temperature not specified in the publication
0.00025
1-((E)-4-(3-(pyridin-3-yl)acrylamido)hexyl)-1,12-dicarba-closo-dodecaborane
Homo sapiens
at 30°C, pH not specified in the publication
0.00037
1-((E)-4-(3-(pyridin-3-yl)acrylamido)hexyl)-1,2-dicarba-closo-dodecaborane
Homo sapiens
at 30°C, pH not specified in the publication
0.0049
1-((E)-4-(3-(pyridin-3-yl)acrylamido)pentyl)-1,2-dicarba-closo-dodecaborane
Homo sapiens
at 30°C, pH not specified in the publication
0.03
1-(4-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)butyl)-1,2-dicarba-closo-dodecaborane
Homo sapiens
IC50 above 0.03 mM, at 30°C, pH not specified in the publication
0.03
1-(4-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)pentyl)-1,2-dicarba-closo-dodecaborane
Homo sapiens
IC50 above 0.03 mM, at 30°C, pH not specified in the publication
0.03
1-(5-(1H-pyrrolo[3,2-c]pyridine-2-carboxamido)butyl)-1,2-dicarba-closo-dodecaborane
Homo sapiens
IC50 above 0.03 mM, at 30°C, pH not specified in the publication
0.03
1-(5-(1H-pyrrolo[3,2-c]pyridine-2-carboxamido)pentyl)-1,2-dicarba-closo-dodecaborane
Homo sapiens
IC50 above 0.03 mM, at 30°C, pH not specified in the publication
0.0000439
1-(pyridin-3-ylmethyl)-3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000324
1-([1,1'-biphenyl]-2-yl)-3-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)urea
Mus musculus
at pH 7.5 and 37°C
0.002
1-methyl-N-[4-(phenylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000003
1-[(6-aminopyridin-3-yl)methyl]-3-[4-(phenylsulfonyl)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication
0.005
1-[2-(naphthalen-2-yloxy)ethyl]-3-(pyridin-3-ylmethyl)urea
Homo sapiens
pH and temperature not specified in the publication
0.00987
1-[3-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000217
1-[4-(morpholin-4-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000845
1-[4-(piperazin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000422
1-[4-(piperidin-1-ylcarbonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.01453
1-[4-(piperidin-1-yloxy)phenyl]-3-(pyridin-3-ylmethyl)guanidine
Homo sapiens
-
at pH 7.5 and 37°C
0.0000989
1-[4-(piperidin-1-yloxy)phenyl]-3-(pyridin-3-ylmethyl)urea
Homo sapiens
-
at pH 7.5 and 37°C
0.000765
1-[4-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)guanidine
Homo sapiens
-
at pH 7.5 and 37°C
0.0000201
1-[4-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000964
1-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-3-(pyridin-3-ylmethyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0038
1H-indol-2-yl(4-[[3-(pyridin-3-yl)-1H-pyrazol-5-yl]carbonyl]piperazin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.0000385
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.0005
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
IC50 above 0.0005 mM, pH and temperature not specified in the publication
0.0005
2'-([7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]carbamoyl)[1,1'-biphenyl]-4-carboxylic acid
Homo sapiens
IC50 above 0.0005 mM, pH and temperature not specified in the publication
0.0000879
2'-[(aminooxy)carbonyl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000206
2-(4-[[4-(1-ethoxyethenyl)piperidin-1-yl]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000247
2-(4-[[4-(propan-2-yl)piperazin-1-yl]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000738
2-(4-[[bis(2-hydroxyethyl)amino]methyl]-1H-1,2,3-triazol-1-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000285
2-(pyridin-3-yl)-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000025
2-cyano-1-[4-(phenylsulfonyl)benzyl]-3-pyridin-4-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.0019
2-[4-[(4-chlorophenyl)sulfamoyl]phenoxy]-N-(pyridin-3-ylmethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0000418
2-[4-[(4-hydroxypiperidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000136
2-[4-[(4-methylpiperazin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000424
2-[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000496
2-[4-[(morpholin-4-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000171
2-[4-[(piperidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]-N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000156
3-(1-(4-(2-([1,1'-biphenyl]-2-yloxy)ethyl)benzyl)-1H-1,2,3-triazol-4-yl)pyridine
Mus musculus
at pH 7.5 and 37°C
0.0000038
3-(1-(6-([1,1'-biphenyl]-2-yloxy)hexyl)-1H-1,2,3-triazol-4-yl)-pyridine
Mus musculus
at pH 7.5 and 37°C
0.0000081
3-(1-(7-(4-([1,1'-biphenyl]-2-yl)-1H-1,2,3-triazol-1-yl)-heptyl)-1H-1,2,3-triazol-4-yl)pyridine
Mus musculus
at pH 7.5 and 37°C
0.0000313
3-(1-(7-([1,1'-biphenyl]-2-yloxy)heptyl)-1H-1,2,3-triazol-4-yl)pyridine
Mus musculus
at pH 7.5 and 37°C
0.0000254
3-(1-(8-([1,1'-biphenyl]-2-yloxy)octyl)-1H-1,2,3-triazol-4-yl)-pyridine
Mus musculus
at pH 7.5 and 37°C
4.162
4-chloro-N-[(5-[[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]sulfamoyl]thiophen-2-yl)methyl]benzamide
Homo sapiens
-
at pH 7.5 and 37°C
0.00022
4-[[(2E)-3-(pyridin-3-yl)prop-2-enoyl]amino]-N-(2,2,2-trifluoroethyl)benzamide
Homo sapiens
pH and temperature not specified in the publication
0.00032
5-(3,4-dichlorobenzyl)-4-oxo-N-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.23
7-chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
Homo sapiens
pH and temperature not specified in the publication
0.166
ethyl [(E)-[4-(piperidine-1-sulfonyl)anilino][[(pyridin-3-yl)methyl]amino]methylidene]carbamate
Homo sapiens
-
at pH 7.5 and 37°C
0.0000009 - 0.008585
FK-866
0.0000068 - 0.00062
FK866
0.0013
gallotanine
Mus musculus
-
i.e. (2R,3S,5R,6S)-tetrahydro-2H-pyran-2,3,4,5,6-pentaylpentakis(oxycarbonyl-5,6-dihydroxybenzene-3,1-diyl) pentakis(3,4,5-trihydroxybenzoate), pH 7.5, 37°C
0.0000017
N''-cyano-N-([4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl]methyl)-N'-pyridin-4-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000044
N''-cyano-N-pyridin-4-yl-N'-([4-[3-(trifluoromethoxy)benzene-1-sulfonyl]phenyl]methyl)guanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000024
N''-cyano-N-pyridin-4-yl-N'-([4-[3-(trifluoromethyl)benzene-1-sulfonyl]phenyl]methyl)guanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000036
N''-cyano-N-pyridin-4-yl-N'-[[4-(quinoline-8-sulfonyl)phenyl]methyl]guanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000006
N''-cyano-N-[[4-(3,5-difluorobenzene-1-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000019
N''-cyano-N-[[4-(3-methoxybenzene-1-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000044
N''-cyano-N-[[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)phenyl]methyl]-N'-pyridin-3-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000024
N''-cyano-N-[[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000054
N''-cyano-N-[[4-(cyclohexanesulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.0000075
N''-cyano-N-[[4-(phenylmethanesulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.000002
N''-cyano-N-[[4-(pyridine-3-sulfonyl)phenyl]methyl]-N'-pyridin-4-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.01
N-(2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-oxoethyl)-3-methylthiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00095
N-(2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-oxoethyl)-5-methylthiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000418
N-(4-butylphenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000014
N-(4-[4-[(1H-benzimidazol-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000099
N-(4-[4-[(2,6-difluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000157
N-(4-[4-[(2-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000123
N-(4-[4-[(2-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000124
N-(4-[4-[(2-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000126
N-(4-[4-[(3-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000089
N-(4-[4-[(3-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000168
N-(4-[4-[(3-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000199
N-(4-[4-[(4-aminophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000242
N-(4-[4-[(4-bromophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000798
N-(4-[4-[(4-butylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000137
N-(4-[4-[(4-chlorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.000012
N-(4-[4-[(4-fluorophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000105
N-(4-[4-[(4-methylphenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000197
N-(4-[4-[(4-nitrophenyl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000191
N-(4-[4-[(furan-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000487
N-(4-[4-[(furan-3-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000295
N-(4-[4-[(naphthalen-2-yl)methyl]piperazine-1-sulfonyl]phenyl)-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.000099
N-(4-[[1-(propan-2-yl)-1H-pyrazol-4-yl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000077
N-(4-[[3-(trifluoromethoxy)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000061
N-(4-[[3-(trifluoromethyl)phenyl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00001
N-(4-[[5-(trifluoromethyl)pyridin-3-yl]sulfonyl]benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000031
N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide
Mus musculus
at pH 7.5 and 37°C
0.0000031
N-(7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl)[1,1'-biphenyl]-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000047
N-(8-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)octyl)biphenyl-2-sulfonamide
Mus musculus
at pH 7.5 and 37°C
0.002
N-(pyridin-4-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000269
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl)octanamide
Mus musculus
at pH 7.5 and 37°C
0.0000499
N-([1,1'-biphenyl]-2-yl)-8-(5-(pyridin-3-yl)isoxazol-3-yl)-octanamide
Mus musculus
at pH 7.5 and 37°C
0.0000102
N-([1,1'-biphenyl]-2-yl)-8-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]octanamide
Mus musculus
at pH 7.5 and 37°C
0.00044
N-([4-[4-(oxetan-3-yl)piperazine-1-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0003
N-([4-[4-(pyrrolidin-1-yl)piperidine-1-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000012
N-([4-[6-(dimethylamino)pyridine-3-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000045
N-([4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl]methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000196
N-benzyl-4-[[(pyridin-3-ylmethyl)carbamothioyl]amino]benzenesulfonamide
Homo sapiens
-
at pH 7.5 and 37°C
0.000022
N-phenyl-4-[[(pyridin-3-ylmethyl)carbamothioyl]amino]benzenesulfonamide
Homo sapiens
-
at pH 7.5 and 37°C
0.0000098
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(pyridin-3-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000137
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(pyridin-4-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000388
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(thiophen-2-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000225
N-[(pyridin-3-yl)methyl]-N'-(4-[4-[(thiophen-3-yl)methyl]piperazine-1-sulfonyl]phenyl)thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000369
N-[(pyridin-3-yl)methyl]-N'-[4-(4-[[4-(trifluoromethoxy)phenyl]methyl]piperazine-1-sulfonyl)phenyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000237
N-[(pyridin-3-yl)methyl]-N'-[4-(4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-sulfonyl)phenyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000177
N-[(pyridin-3-yl)methyl]-N'-[4-[4-(pyridin-2-yl)piperazine-1-sulfonyl]phenyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0014
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-benzofuran-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00015 - 0.149
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-benzothiophene-2-carboxamide
0.0053
N-[2-(3,4-dimethoxyphenyl)ethyl]-3-methylthiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00086
N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methylthiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.01
N-[2-(3,4-dimethoxyphenyl)ethyl]-5-nitrothiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.001
N-[3-(1H-imidazol-1-yl)propyl]-1-benzofuran-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0011
N-[3-(1H-imidazol-1-yl)propyl]-1-benzothiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.01
N-[3-(1H-imidazol-1-yl)propyl]-3-methylthiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00017
N-[3-(1H-imidazol-1-yl)propyl]-5-methylthiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.01
N-[3-(1H-imidazol-1-yl)propyl]-5-nitrothiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000051
N-[4-(1-propyl-1H-pyrazole-3-sulfonyl)phenyl]-2-(pyridin-3-yl)cyclopropane-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000405
N-[4-(4-acetylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000009
N-[4-(4-benzylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0000142
N-[4-(4-cyclohexylpiperazine-1-sulfonyl)phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.00037
N-[4-(morpholin-4-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000066
N-[4-(phenylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.002
N-[4-(phenylsulfonyl)benzyl]-1H-pyrazolo[3,4-c]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.002
N-[4-(phenylsulfonyl)benzyl]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000029
N-[4-(phenylsulfonyl)benzyl]-1H-pyrrolo[3,2-c]pyridine-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000043
N-[4-(phenylsulfonyl)benzyl]-5-(pyridin-3-yl)-1H-pyrazole-3-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.018
N-[4-(phenylsulfonyl)benzyl]imidazo[1,2-a]pyridine-6-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.002
N-[4-(piperidin-1-ylsulfonyl)benzyl]-1H-indazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000088
N-[4-(piperidin-1-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.028
N-[4-(piperidin-1-ylsulfonyl)benzyl]imidazo[1,2-a]pyridine-6-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000082
N-[4-(quinolin-3-ylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00019
N-[4-[(1-ethyl-1H-pyrazol-4-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00001
N-[4-[(1-propyl-1H-pyrazol-4-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000079
N-[4-[(3,5-difluorophenyl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00041
N-[4-[(4-cyanopiperidin-1-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00041
N-[4-[(4-hydroxypiperidin-1-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
6.443
N-[4-[(4E)-4-(2,3-dimethoxybenzylidene)-5-oxo-4,5-dihydro-1,3-oxazol-2-yl]phenyl]thiophene-2-carboxamide
Homo sapiens
-
at pH 7.5 and 37°C
0.000011
N-[4-[(5-chloropyridin-3-yl)sulfonyl]benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000154
N-[4-[4-(4-methylphenyl)piperazine-1-sulfonyl]phenyl]-N'-[(pyridin-3-yl)methyl]thiourea
Homo sapiens
-
at pH 7.5 and 37°C
0.0005
N-[7-[4-(1-oxo-1lambda(5)-pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl][1,1'-biphenyl]-2-carboxamide
Homo sapiens
IC50 above 0.0005 mM, pH and temperature not specified in the publication
0.0000034
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-(1H-1,2,3-triazol-1-yl)benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000425
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-(1H-1,2,3-triazol-4-yl)benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000254
N-[7-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]heptyl]-2-[4-[(pyrrolidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.00039
N-[[4-(4-aminopiperidine-1-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0004
N-[[4-(4-methoxypiperidine-1-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00011
N-[[4-(7-oxa-2-azaspiro[3.5]nonane-2-sulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000063
N-[[4-(benzenesulfonyl)phenyl]methyl]-1,1-dioxo-2H-pyrido[4,3-e][1,2,4]thiadiazin-3-amine
Homo sapiens
pH and temperature not specified in the publication
0.0013
N-[[4-(benzenesulfonyl)phenyl]methyl]-1H-pyrazolo[4,3-b]pyridine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000022
N-[[4-(benzenesulfonyl)phenyl]methyl]-N''-cyano-N'-pyridin-3-ylguanidine
Homo sapiens
pH and temperature not specified in the publication
0.03
tert-butyl ((1,12-dicarba-closo-dodecaboranylamido)propyl)carbamate
Homo sapiens
IC50 above 0.03 mM, at 30°C, pH not specified in the publication
0.0000217
tert-butyl 4-[4-([[(pyridin-3-yl)methyl]carbamothioyl]amino)benzene-1-sulfonyl]piperazine-1-carboxylate
Homo sapiens
-
at pH 7.5 and 37°C
0.002
tert-butyl trans-1-(2-(pyridin-3-yl)cyclopropanecarbonyl)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate
Homo sapiens
pH and temperature not specified in the publication
0.002
tert-butyl trans-6-(2-(pyridin-3-yl)cyclopropanecarbonyl)-2,6-diazaspiro[3.4]octane-2-carboxylate
Homo sapiens
pH and temperature not specified in the publication
0.00046
trans-(R,R)-N-(4-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000005
trans-(S,S)-N-(4-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000051
trans-(S,S)-N-(4-((1-propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.002
trans-2-(6-aminopyridin-3-yl)-N-(4-(phenylsulfonyl)benzyl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000049
trans-2-(6-aminopyridin-3-yl)-N-(4-(phenylsulfonyl)phenyl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00001
trans-2-(pyridin-3-yl)-N-(4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000066
trans-2-(pyridin-3-yl)-N-(4-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000095
trans-2-(pyridin-3-yl)-N-(4-((3-(trifluoromethoxy)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00001
trans-2-(pyridin-3-yl)-N-(4-((3-(trifluoromethyl)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000036
trans-2-(pyridin-3-yl)-N-(4-((tetrahydro-2H-pyran-4-yl)-sulfonyl)phenyl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0016
trans-2-phenyl-N-(pyridin-4-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000002
trans-N-(4-((1-(2-Hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)-sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000009
trans-N-(4-((1-ethyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000001
trans-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000038
trans-N-(4-((1-isopropyl-3-methyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000011
trans-N-(4-((1-isopropyl-5-methyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000072
trans-N-(4-((1-propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000012
trans-N-(4-((3,5-difluorophenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000044
trans-N-(4-((3-(methylsulfonyl)phenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000012
trans-N-(4-((6-methylpyridin-3-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000047
trans-N-(4-(1-benzoylpiperidin-4-yl)butyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000088
trans-N-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-ylsulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000021
trans-N-(4-(morpholinosulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0015
trans-N-(4-(phenylsulfonyl)benzyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.002
trans-N-(4-(phenylsulfonyl)benzyl)-2-(pyridin-4-yl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000078
trans-N-(4-(phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0013
trans-N-(4-(phenylsulfonyl)phenyl)-2-(pyridin-4-yl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000076
trans-N-(6-(4-chlorophenoxy)hexyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0002427
[4-(diphenylmethyl)piperazin-1-yl][5-(pyridin-3-yl)-1H-pyrazol-3-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.0000027
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.0000049
(2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide
Mus musculus
at pH 7.5 and 37°C
0.0000009
FK-866
Mus musculus
-
i.e. (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-phenylprop-2-enamide, pH 7.5, 37°C
0.00011
FK-866
Homo sapiens
wild type protein, pH 8.5, 37°C
0.008585
FK-866
Homo sapiens
H191R mutant protein, pH 8.5, 37°C
0.0000068
FK866
Homo sapiens
pH and temperature not specified in the publication
0.00062
FK866
Homo sapiens
at 30°C, pH not specified in the publication
0.00015
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-benzothiophene-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.149
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-benzothiophene-2-carboxamide
Homo sapiens
-
at pH 7.5 and 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Preiss, J.; Handler, P.
Enzymatic synthesis of nicotinamide mononucleotide
J. Biol. Chem.
225
759-770
1957
Homo sapiens
brenda
Lin, L.F.H.; Lan, S.J.; Richardson, A.H.; Henderson, L.V.M.
Pyridine nucleotide synthesis. Purification of nicotinamide mononucleotide pyrophosphorylase from rat erythrocytes
J. Biol. Chem.
247
8016-8022
1972
Rattus norvegicus
brenda
Dietrich, L.S.; Muniz, O.
Inhibition of nicotinamide phosphoribosyltransferase by pyridine nucleotides
Biochemistry
11
1691-1695
1972
Rattus norvegicus
brenda
Elliott, G.C.; Rechsteiner, M.C.
Evidence for a physiologically active nicotinamide phosphoribosyltransferase in cultured human fibroblasts
Biochem. Biophys. Res. Commun.
104
996-1002
1982
Homo sapiens
brenda
Shibata, K.; Taguchi, H.; Nishitani, H.; Okumura, K.; Shimabayashi, Y.; Matsushita, N.; Yamazaki, H.
End product inhibition of the activity of nicotinamide phosphoribosyltransferase from various tissues of rats by NAD
Agric. Biol. Chem.
53
2283-2284
1989
Rattus norvegicus
-
brenda
Rocchigiani, M.; Micheli, V.; Duley, J.A.; Simmonds, H.A.
Determination of nicotinamide phosphoribosyltransferase activity in human erythrocytes: high-performance liquid chromatography-linked method
Anal. Biochem.
205
334-336
1992
Homo sapiens
brenda
Rongvaux, A.; Shea, R.J.; Mulks, M.H.; Gigot, D.; Urbain, J.; Leo, O.; Andris, F.
Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis
Eur. J. Immunol.
32
3225-3234
2002
Mus musculus
brenda
Martin, P.R.; Shea, R.J.; Mulks, M.H.
Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence
J. Bacteriol.
183
1168-1174
2001
[Haemophilus] ducreyi
brenda
Hasmann, M.; Schemainda, I.
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis
Cancer Res.
63
7436-7442
2003
Homo sapiens
brenda
Revollo, J.R.; Grimm, A.A.; Imai, S.
The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells
J. Biol. Chem.
279
50754-50763
2004
Mus musculus (Q99KQ4), Mus musculus
brenda
Takahashi, R.; Nakamura, S.; Yoshida, T.; Kobayashi, Y.; Ohkubo, T.
Crystallization of human nicotinamide phosphoribosyltransferase
Acta Crystallogr. Sect. F
F63
375-377
2007
Homo sapiens (P43490), Homo sapiens
brenda
van der Veer, E.; Ho, C.; ONeil, C.; Barbosa, N.; Scott, R.; Cregan, S.P.; Pickering, J.G.
Extension of human cell lifespan by nicotinamide phosphoribosyltransferase
J. Biol. Chem.
282
10841-10845
2007
Homo sapiens, Homo sapiens (P43490)
brenda
Kim, M.K.; Lee, J.H.; Kim, H.; Park, S.J.; Kim, S.H.; Kang, G.B.; Lee, Y.S.; Kim, J.B.; Kim, K.K.; Suh, S.W.; Eom, S.H.
Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866
J. Mol. Biol.
362
66-77
2006
Rattus norvegicus (Q80Z29)
brenda
Khan, J.A.; Tao, X.; Tong, L.
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents
Nat. Struct. Mol. Biol.
13
582-588
2006
Homo sapiens (P43490), Homo sapiens, Mus musculus (Q99KQ4), Mus musculus
brenda
Ashihara, H.; Stasolla, C.; Yin, Y.; Loukanina, N.; Thorpe, T.A.
De novo and salvage biosynthetic pathways of pyridine nucleotides and nicotinic acid conjugates in cultured plant cells
Plant Sci.
169
107-114
2005
no activity in Picea glauca
brenda
Takahashi, R.; Nakamura, S.; Yoshida, T.; Kobayashi, Y.; Ohkubo, T.
Crystallization of human nicotinamide phosphoribosyltransferase
Acta Crystallogr. Sect. F
63
375-377
2007
Homo sapiens (P43490), Homo sapiens
brenda
Burgos, E.S.; Schramm, V.L.
Weak Coupling of ATP Hydrolysis to the Chemical Equilibrium of Human Nicotinamide Phosphoribosyltransferase
Biochemistry
47
11086-11096
2008
Homo sapiens (P43490), Homo sapiens
brenda
Mercader, J.; Granados, N.; Caimari, A.; Oliver, P.; Bonet, M.L.; Palou, A.
Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models
Horm. Metab. Res.
40
467-472
2008
Rattus norvegicus (Q80Z29), Rattus norvegicus
brenda
Busso, N.; Karababa, M.; Nobile, M.; Rolaz, A.; Van Gool, F.; Galli, M.; Leo, O.; So, A.; De Smedt, T.
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD
PLoS ONE
3
e2267
2008
Homo sapiens (P43490), Mus musculus (Q99KQ4)
brenda
Beauparlant, P.; Bedard, D.; Bernier, C.; Chan, H.; Gilbert, K.; Goulet, D.; Gratton, M.O.; Lavoie, M.; Roulston, A.; Turcotte, E.; Watson, M.
Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777
Anticancer Drugs
20
346-354
2009
Homo sapiens, Mus musculus
brenda
Garten, A.; Petzold, S.; Barnikol-Oettler, A.; Koerner, A.; Thasler, W.E.; Kratzsch, J.; Kiess, W.; Gebhardt, R.
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes
Biochem. Biophys. Res. Commun.
391
376-381
2010
Homo sapiens
brenda
Hsu, C.P.; Oka, S.; Shao, D.; Hariharan, N.; Sadoshima, J.
Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes
Circ. Res.
105
481-491
2009
Mus musculus
brenda
Takahashi, R.; Nakamura, S.; Nakazawa, T.; Minoura, K.; Yoshida, T.; Nishi, Y.; Kobayashi, Y.; Ohkubo, T.
Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase
J. Biochem.
147
95-107
2010
Homo sapiens (P43490), Homo sapiens
brenda
Colombano, G.; Travelli, C.; Galli, U.; Caldarelli, A.; Chini, M.G.; Canonico, P.L.; Sorba, G.; Bifulco, G.; Tron, G.C.; Genazzani, A.A.
A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry
J. Med. Chem.
53
616-623
2010
Homo sapiens (P43490)
brenda
Zhang, R.Y.; Qin, Y.; Lv, X.Q.; Wang, P.; Xu, T.Y.; Zhang, L.; Miao, C.Y.
A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase
Anal. Biochem.
412
18-25
2011
Mus musculus
brenda
Olesen, U.; Petersen, J.; Garten, A.; Kiess, W.; Yoshino, J.; Imai, S.; Christensen, M.; Fristrup, P.; Thougaard, A.; Bjrkling, F.; Jensen, P.; Nielsen, S.; Sehested, M.
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
BMC Cancer
10
677
2010
Homo sapiens (P43490)
brenda
Friebe, D.; Neef, M.; Kratzsch, J.; Erbs, S.; Dittrich, K.; Garten, A.; Petzold-Quinque, S.; Blueher, S.; Reinehr, T.; Stumvoll, M.; Blueher, M.; Kiess, W.; Koerner, A.
Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans
Diabetologia
54
1200-1211
2011
Homo sapiens
brenda
Dahl, T.; Ranheim, T.; Holm, S.; Berge, R.; Aukrust, P.; Halvorsen, B.
Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages
Eur. J. Clin. Invest.
41
1098-1104
2011
Homo sapiens
brenda
Zhang, L.Q.; Heruth, D.P.; Ye, S.Q.
Nicotinamide phosphoribosyltransferase in human diseases
J. Bioanal. Biomed.
3
13-25
2011
Homo sapiens (P43490), Homo sapiens
brenda
Pittelli, M.; Formentini, L.; Faraco, G.; Lapucci, A.; Rapizzi, E.; Cialdai, F.; Romano, G.; Moneti, G.; Moroni, F.; Chiarugi, A.
Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool
J. Biol. Chem.
285
34106-34114
2010
Homo sapiens
brenda
Hong, E.H.; Yun, H.S.; Kim, J.; Um, H.D.; Lee, K.H.; Kang, C.M.; Lee, S.J.; Chun, J.S.; Hwang, S.G.
Nicotinamide phosphoribosyltransferase is essential for interleukin-1beta-mediated dedifferentiation of articular chondrocytes via SIRT1 and extracellular signal-regulated kinase (ERK) complex signaling
J. Biol. Chem.
286
28619-28631
2011
Oryctolagus cuniculus
brenda
Zhang, H.S.; Sang, W.W.; Wang, Y.O.; Liu, W.
Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation
J. Cell. Biochem.
110
1464-1470
2010
Homo sapiens
brenda
Hara, N.; Yamada, K.; Shibata, T.; Osago, H.; Tsuchiya, M.
Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma
PLoS ONE
6
e22781
2011
Homo sapiens
brenda
Bowlby, S.C.; Thomas, M.J.; D'Agostino, R.B.; Kridel, S.J.
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells
PLoS ONE
7
e40195
2012
Homo sapiens
brenda
Liu, L.; Wang, F.; Zhang, X.; Huang, P.; Lu, Y.; Wei, E.; Zhang, W.
Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases
PLoS ONE
7
e44933
2012
Mus musculus
brenda
Zheng, X.; Bair, K.W.; Bauer, P.; Baumeister, T.; Bowman, K.K.; Buckmelter, A.J.; Caligiuri, M.; Clodfelter, K.H.; Feng, Y.; Han, B.; Ho, Y.C.; Kley, N.; Li, H.; Liang, X.; Liederer, B.M.; Lin, J.; Ly, J.; OBrien, T.; Oeh, J.; Oh, A.; Reynolds, D.J.; Sampath, D.; Sharma, G.; Skelton, N.; Smith, C.C.; Tremayne, J.
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)
Bioorg. Med. Chem. Lett.
23
5488-5497
2013
Homo sapiens (P43490), Homo sapiens
brenda
Zheng, X.; Baumeister, T.; Buckmelter, A.J.; Caligiuri, M.; Clodfelter, K.H.; Han, B.; Ho, Y.C.; Kley, N.; Lin, J.; Reynolds, D.J.; Sharma, G.; Smith, C.C.; Wang, Z.; Dragovich, P.S.; Oh, A.; Wang, W.; Zak, M.; Wang, Y.; Yuen, P.W.; Bair, K.W.
Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors
Bioorg. Med. Chem. Lett.
24
337-343
2014
Homo sapiens (P43490)
brenda
Clark, D.E.; Waszkowycz, B.; Wong, M.; Lockey, P.M.; Adalbert, R.; Gilley, J.; Clark, J.; Coleman, M.P.
Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies
Bioorg. Med. Chem. Lett.
26
2920-2926
2016
Homo sapiens (P43490)
brenda
Chen, W.; Dong, G.; He, S.; Xu, T.; Wang, X.; Liu, N.; Zhang, W.; Miao, C.; Sheng, C.
Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase
Bioorg. Med. Chem. Lett.
26
765-768
2016
Homo sapiens (P43490), Homo sapiens
brenda
Grolla, A.A.; Travelli, C.; Genazzani, A.A.; Sethi, J.K.
Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine
Br. J. Pharmacol.
173
2182-2194
2016
Homo sapiens (P43490)
brenda
Hsu, C.P.; Yamamoto, T.; Oka, S.; Sadoshima, J.
The function of nicotinamide phosphoribosyltransferase in the heart
DNA Repair
23
64-68
2014
Homo sapiens (P43490)
brenda
Fang, C.; Guan, L.; Zhong, Z.; Gan, X.; He, S.
Analysis of the nicotinamide phosphoribosyltransferase family provides insight into vertebrate adaptation to different oxygen levels during the water-to-land transition
FEBS J.
282
2858-2878
2015
Danio rerio
brenda
Marletta, A.S.; Massarotti, A.; Orsomando, G.; Magni, G.; Rizzi, M.; Garavaglia, S.
Crystal structure of human nicotinic acid phosphoribosyltransferase
FEBS Open Bio
5
419-428
2015
Homo sapiens (P43490), Homo sapiens
brenda
Pittelli, M.; Cavone, L.; Lapucci, A.; Oteri, C.; Felici, R.; Niccolai, E.; Amedei, A.; Chiarugi, A.
Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes
Immunol. Cell Biol.
92
191-199
2014
Homo sapiens (P43490), Homo sapiens, Mus musculus
brenda
Tan, B.; Young, D.; Lu, Z.; Wang, T.; Meier, T.; Shepard, R.; Roth, K.; Zhai, Y.; Huss, K.; Kuo, M.; Gillig, J.; Parthasarathy, S.; Burkholder, T.; Smith, M.; Geeganage, S.; Zhao, G.
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: Metabolic basis and potential clinical implications
J. Biol. Chem.
288
3500-3511
2013
Homo sapiens (P43490), Homo sapiens
brenda
Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A.J.; Caligiuri, M.; Clodfelter, K.H.; Han, B.; Ho, Y.C.; Kley, N.; Lin, J.; Reynolds, D.J.; Sharma, G.; Smith, C.C.; Wang, Z.; Dragovich, P.S.; Gunzner-Toste, J.; Liederer, B.M.; Ly, J.; OBrien, T.; Oh, A.; Wang, L.; Wang, W.; Xiao, Y.; Zak, M.; Zhao, G.; Yue, Y.u.e.n.
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors
J. Med. Chem.
56
6413-6433
2013
Homo sapiens (P43490)
brenda
Xu, T.Y.; Zhang, S.L.; Dong, G.Q.; Liu, X.Z.; Wang, X.; Lv, X.Q.; Qian, Q.J.; Zhang, R.Y.; Sheng, C.Q.; Miao, C.Y.
Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase
Sci. Rep.
5
10043
2015
Homo sapiens
brenda
Zabka, T.S.; Singh, J.; Dhawan, P.; Liederer, B.M.; Oeh, J.; Kauss, M.A.; Xiao, Y.; Zak, M.; Lin, T.; McCray, B.; La, N.; Nguyen, T.; Beyer, J.; Farman, C.; Uppal, H.; Dragovich, P.S.; OBrien, T.; Sampath, D.; Misner, D.L.
Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase
Toxicol. Sci.
144
163-172
2015
Homo sapiens (P43490), Homo sapiens, Rattus norvegicus (Q80Z29)
brenda
Oita, R.C.; Camp, S.M.; Ma, W.; Ceco, E.; Harbeck, M.; Singleton, P.; Messana, J.; Sun, X.; Wang, T.; Garcia, J.G.N.
Novel mechanism for nicotinamide phosphoribosyltransferase inhibition of TNF-alpha-mediated apoptosis in human lung endothelial cells
Am. J. Respir. Cell Mol. Biol.
59
36-44
2018
Homo sapiens (P43490), Homo sapiens
brenda
Molugu, T.R.; Oita, R.C.; Chawla, U.; Camp, S.M.; Brown, M.F.; Garcia, J.G.N.
Nicotinamide phosphoribosyltransferase purification using SUMO expression system
Anal. Biochem.
598
113597
2020
Mus musculus (Q99KQ4)
brenda
Asawa, Y.; Katsuragi, K.; Sato, A.; Yoshimori, A.; Tanuma, S.I.; Nakamura, H.
Structure-based drug design of novel carborane-containing nicotinamide phosphoribosyltransferase inhibitors
Bioorg. Med. Chem.
27
2832-2844
2019
Homo sapiens (P43490)
brenda
Curtin, M.L.; Heyman, H.R.; Clark, R.F.; Sorensen, B.K.; Doherty, G.A.; Hansen, T.M.; Frey, R.R.; Sarris, K.A.; Aguirre, A.L.; Shrestha, A.; Tu, N.; Woller, K.; Pliushchev, M.A.; Sweis, R.F.; Cheng, M.; Wilsbacher, J.L.; Kovar, P.J.; Guo, J.; Cheng, D.; Longenecker, K.L.; Raich, D.; Korepanova, A.V.; Soni, N.B.; Algire, M.A.
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)
Bioorg. Med. Chem. Lett.
27
3317-3325
2017
Homo sapiens (P43490)
brenda
Zhang, K.; Ni, Y.; Chen, J.; Tu, Z.; Wu, X.; Chen, D.; Yao, H.; Jiang, S.
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer
Bioorg. Med. Chem. Lett.
29
1502-1506
2019
Homo sapiens (P43490)
brenda
Zhang, L.Q.; Van Haandel, L.; Xiong, M.; Huang, P.; Heruth, D.P.; Bi, C.; Gaedigk, R.; Jiang, X.; Li, D.Y.; Wyckoff, G.; Grigoryev, D.N.; Gao, L.; Li, L.; Wu, M.; Leeder, J.S.; Ye, S.Q.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase
Cell Death Dis.
8
e2705
2017
Mus musculus (Q99KQ4), Mus musculus
brenda
Torretta, S.; Colombo, G.; Travelli, C.; Boumya, S.; Lim, D.; Genazzani, A.A.; Grolla, A.A.
The cytokine nicotinamide phosphoribosyltransferase (eNAMPT; PBEF; visfatin) acts as a natural antagonist of C-C chemokine receptor type 5 (CCR5)
Cells
9
496
2020
Homo sapiens (P43490), Mus musculus (Q99KQ4)
brenda
Aprile, S.; Galli, U.; Tron, G.C.; Del Grosso, E.; Travelli, C.; Grosa, G.
Data on metabolic stability, aqueous solubility and CYP inhibition of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors
Data Brief
28
105034
2020
Homo sapiens (P43490)
brenda
Travelli, C.; Aprile, S.; Mattoteia, D.; Colombo, G.; Clemente, N.; Scanziani, E.; Terrazzino, S.; Alisi, M.A.; Polenzani, L.; Grosa, G.; Genazzani, A.A.; Tron, G.C.; Galli, U.
Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group
Eur. J. Med. Chem.
181
111576
2019
Homo sapiens (P43490)
brenda
Kong, J.; Du, C.; Jiang, L.; Jiang, W.; Deng, P.; Shao, X.; Zhang, B.; Li, Y.; Zhu, R.; Zhao, Q.; Fu, D.; Gu, H.; Luo, L.; Long, H.; Zhao, Y.; Cen, X.
Nicotinamide phosphoribosyltransferase regulates cocaine reward through sirtuin 1
Exp. Neurol.
307
52-61
2018
Mus musculus (Q99KQ4)
brenda
Feng, D.; Xu, D.; Murakoshi, N.; Tajiri, K.; Qin, R.; Yonebayashi, S.; Okabe, Y.; Li, S.; Yuan, Z.; Aonuma, K.; Ieda, M.
Nicotinamide phosphoribosyltransferase (Nampt)/nicotinamide adenine dinucleotide (NAD) axis suppresses atrial fibrillation by modulating the calcium handling pathway
Int. J. Mol. Sci.
21
4655
2020
Mus musculus (Q99KQ4)
brenda
Svoboda, P.; Krizova, E.; Sestakova, S.; Vapenkova, K.; Knejzlik, Z.; Rimpelova, S.; Rayova, D.; Volfova, N.; Krizova, I.; Rumlova, M.; Sykora, D.; Kizek, R.; Haluzik, M.; Zidek, V.; Zidkova, J.; Skop, V.
Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle-dependent in mammalian cells, and its inhibition slows cell growth
J. Biol. Chem.
294
8676-8689
2019
Homo sapiens (P43490), Mus musculus (Q99KQ4)
brenda
Travelli, C.; Aprile, S.; Rahimian, R.; Grolla, A.A.; Rogati, F.; Bertolotti, M.; Malagnino, F.; di Paola, R.; Impellizzeri, D.; Fusco, R.; Mercalli, V.; Massarotti, A.; Stortini, G.; Terrazzino, S.; Del Grosso, E.; Fakhfouri, G.; Troiani, M.P.; Alisi, M.A.; Grosa, G.; Sorba, G.; Canonico, P.L.; Orsomando, G.
Identification of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors endowed with antiproliferative and antiinflammatory activity
J. Med. Chem.
60
1768-1792
2017
Mus musculus (Q99KQ4)
brenda
Szefler, B.; Czelen, P.
Potential inhibitory effect of indolizine derivatives on the two enzymes nicotinamide phosphoribosyltransferase and beta lactamase, a molecular dynamics study
J. Mol. Model.
23
208
2017
Homo sapiens (P43490)
brenda
Huang, X.; Xing, S.; Chen, C.; Yu, Z.; Chen, J.
Salidroside protects PC12 cells from Abeta1-40-induced cytotoxicity by regulating the nicotinamide phosphoribosyltransferase signaling pathway
Mol. Med. Rep.
16
2700-2706
2017
Rattus norvegicus (Q80Z29)
brenda
Hara, N.; Osago, H.; Hiyoshi, M.; Kobayashi-Miura, M.; Tsuchiya, M.
Quantitative analysis of the effects of nicotinamide phosphoribosyltransferase induction on the rates of NAD+ synthesis and breakdown in mammalian cells using stable isotope-labeling combined with mass spectrometry
PLoS ONE
14
e0214000
2019
Homo sapiens (P43490), Rattus norvegicus (Q80Z29), Mus musculus (Q99KQ4)
brenda
Gao, H.; Chen, J.; Chen, T.; Wang, Y.; Song, Y.; Dong, Y.; Zhao, S.; Machado, R.F.
MicroRNA410 inhibits pulmonary vascular remodeling via regulation of nicotinamide phosphoribosyltransferase
Sci. Rep.
9
9949
2019
Homo sapiens (P43490), Homo sapiens
brenda
Audrito, V.; Manago, A.; Gaudino, F.; Deaglio, S.
Targeting metabolic reprogramming in metastatic melanoma The key role of nicotinamide phosphoribosyltransferase (NAMPT)
Semin. Cell Dev. Biol.
98
192-201
2020
Homo sapiens (P43490)
brenda